(Q37903038)

25 August 2017

1 reference

title

Chronic lymphocytic leukemia in less fit patients: "slow-go". (English)

1 reference

chronic lymphocytic leukemia

25 August 2017

0 references

1 reference

1 reference

3

Robin Foà

1 reference

25 August 2017

Ilaria Del Giudice

1

1 reference

25 August 2017

Francesca Romana Mauro

series ordinal

2

1 reference

25 August 2017

publication date

13 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

52

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

2207-2216

1 reference

Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

New prognostic markers in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

ESH–SIOG International Conference on Haematological Malignancies in the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Treatment of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

State-of-the-art treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Quality of life in chronic lymphocytic leukemia: a neglected issue.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Comprehensive geriatric assessment for older patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Comorbidity and functional status are independent in older cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606386

10.3109/10428194.2011.606386

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference